LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

Following mixed study results, the partners have backed away from seeking broad clearance of dato-dxd in lung cancer and ...

After feedback from the FDA, the companies have voluntarily withdrawn the previous biologics licensing application for ...

AstraZeneca and Daiichi Sankyo have submitted a new Biologics License Application (BLA) for accelerated approval in the US ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

The pharmaceutical giant expects overall sales and core earnings per share to rise by a high-teens percentage at constant ...

VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...

Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...

AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...

AstraZeneca shared the topline result ... developed by Array BioPharma before AZ licensed the drug in 2003. The MEK 1/2 ...

AstraZeneca raises its fiscal 2024 guidance for the second consecutive quarter. This upgrade comes despite ongoing legal ...